Approximately 90% of cancer patients with metastatic breast, prostate, lung or colon cancers develop resistance to chemotherapy. Despite scientific advances, cancer treatment failure due to treatment resistance is a major problem in oncology.
OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) has focused its efforts on the development of therapeutics that target important mechanisms of cancer treatment resistance with the potential to improve treatment outcomes for patients with a variety of cancers.
The company was established in May 2000 as a spin-out from the Prostate Centre at Vancouver General Hospital and the University of British Columbia. It was co-founded by urologist Martin Gleave, MD, and Scott Cormack, OncoGenex' President and CEO, initially to develop and commercialize custirsen (OGX-011), which was...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|